692 results on '"Yeung, David T."'
Search Results
2. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
3. Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol
4. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism
5. Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia
6. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
7. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
8. Supporting discovery and development of medical countermeasures for chemical injury to eye and skin
9. HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort
10. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
11. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
12. The Kv7 Modulator, Retigabine, is an Efficacious Antiseizure Drug for Delayed Treatment of Organophosphate-induced Status Epilepticus
13. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
14. Elements of successful NIH grant applications
15. Special Issue “Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms”
16. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant
17. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease
18. Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus
19. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study
20. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
21. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
22. The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
23. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
24. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib
25. Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study
26. Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia
27. Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients
28. Evaluating the broad-spectrum efficacy of the acetylcholinesterase oximes reactivators MMB4 DMS, HLö-7 DMS, and 2-PAM Cl against phorate oxon, sarin, and VX in the Hartley guinea pig
29. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
30. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
31. Kinetic analysis of oxime-assisted reactivation of human, Guinea pig, and rat acetylcholinesterase inhibited by the organophosphorus pesticide metabolite phorate oxon (PHO)
32. National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)—August 6/7, 2019
33. Overlapping Science in Radiation and Sulfur Mustard Exposures of Skin and Lung: Consideration of Models, Mechanisms, Organ Systems, and Medical Countermeasures
34. Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients
35. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure
36. An Overview of the NIAID/NIH Chemical Medical Countermeasures Product Research and Development Program *
37. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis
38. Case report: Rare case of donor cell‐derived T‐cell acute lymphoblastic leukaemia in a female patient after receiving an allo‐transplant from her male sibling
39. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha
40. Early cessation of calcineurin inhibitors is feasible post haploidentical blood stem cell transplant-the ANZHIT-1 study
41. Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression
42. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
43. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
44. Incidence of Decreased Bone Mineral Density Post Allogeneic Haemopoietic Stem Cell Transplant: Single Institution Retrospective Analysis
45. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Vs Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
46. Outcomes of ABO Incompatible Allogeneic Haematopoietic Stem Cell Transplant: A Single-Centre Retrospective Cohort Review
47. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
48. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients
49. A novel sulfur mustard (HD) vapor inhalation exposure system for accurate inhaled dose delivery
50. Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.